Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas

Eur J Nucl Med Mol Imaging. 2024 Mar;51(4):1060-1069. doi: 10.1007/s00259-023-06523-7. Epub 2023 Nov 27.

Abstract

Purpose: To examine whether adherence to a low-iodine diet (LID) enhances the therapeutic efficacy of radioiodine therapy (RAI) in Graves' hyperthyroidism (GH) in iodine-rich areas.

Methods: We retrospectively evaluated 185 patients with GH from Aichi (n = 114) and Hokkaido (n = 71) Prefectures. Patients aged ≥ 18 years with GH who underwent RAI between December 2012 and March 2022 were divided into subgroups based on pretreatment with anti-thyroid drug (ATD) or potassium iodide (KI). Patients were followed up with LID from 18 days (group A) or 7 days (group H) before RAI to 3 days after RAI. The dose of radioactive iodine 131 (131I) was adjusted to deliver > 100 Gy to the thyroid. The associations between urinary iodine concentration on UIC2 vs. 24hRU and UIC2 vs. the 1-year RAI success rate (SR) were investigated.

Results: Compared with UIC1, UIC2 was significantly decreased in all subgroups (P < 0.01). An inverse correlation between UIC2 and 24hRU was observed in the four groups; however, the difference was insignificant. The SR in groups A and H was 85% and 89%, respectively. Univariate analysis revealed no association between UIC2 and SR in each group. Additionally, stratification of the 185 patients into quartiles using UIC2 yielded no significant differences in SR (p = 0.79).

Conclusions: LID sufficiently reduced UIC in patients undergoing RAI. Although a lower UIC2 may increase 24hRU, it did not increase the success of RAI. The benefit of LID in enhancing the efficacy of RAI in GH treatment remains uncertain.

Keywords: Graves’ hyperthyroidism; Iodine-rich areas; Low iodine diet; Radioiodine therapy; Urinary iodine concentration.

MeSH terms

  • Diet
  • Graves Disease* / drug therapy
  • Graves Disease* / radiotherapy
  • Humans
  • Hyperthyroidism*
  • Iodine Radioisotopes / adverse effects
  • Iodine* / therapeutic use
  • Potassium
  • Retrospective Studies
  • Thyroid Neoplasms* / drug therapy
  • Treatment Outcome

Substances

  • Iodine Radioisotopes
  • Iodine
  • Potassium